Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

A Novel Approach: Fighting Painkiller Addiction at Home

By Marilynn Marchionne, AP Chief Medical Writer | December 28, 2016

University of Vermont Psychologist Stacey Sigmon holds a tamper-proof electronic pill dispenser in her office in Burlington, Vt., Wednesday, Dec. 21, 2016. People hooked on prescription painkillers were able to use the device to take a drug at home to curb cravings and prevent abuse while waiting to get in a treatment program. In results published in the New England Journal of Medicine on Thursday, Dec. 22, 2016, use of the device showed dramatic results in helping people who use the system to remain free of illicit opioids. (AP Photo/Wilson Ring)

People hooked on prescription painkillers were able to use a drug at home to curb cravings and prevent abuse while waiting to get in a treatment program, finds a small study that gives hope for a new way to fight the opioid problem.

The drug used in the study is usually only given under supervision of a doctor or in settings like jails or treatment programs, but waiting lists are often months long at many clinics.

“Folks are dying, overdosing, contracting HIV and hepatitis on wait lists,” said Stacey Sigmon, a psychologist and drug abuse researcher at the University of Vermont.

She sought a way to tide people over, using a tamper-resistant electronic pill dispenser to allow home use.

The drug, buprenorphine, also sold as Suboxone, attaches to the same brain receptors that opioids like OxyContin, heroin and Vicodin do, so it eases withdrawal symptoms and prevents a “high” if those other drugs are used. Buprenorphine itself is an opioid, so it, too, can be abused at high doses, but it is chemically different and has somewhat less potential for that.

“We programmed the device to make each day’s dose only available in a three-hour period,” she said. Users had to see researchers regularly for pill counts and drug tests, and got daily phone calls to check on how they were.

Results were dramatic. Of the 25 people given the device, 88 percent tested free of illicit opioids at four weeks. At eight weeks it was 84 percent and at 12 weeks, 68 percent. None of 25 others in the study who got no anti-addiction care tested clean at any point.

“It’s a huge effect. It is a remarkable difference in outcomes,” said Dr. Nora Volkow, director of the National Institute on Drug Abuse.

A grant from the U.S. government paid for the pilot study; researchers are seeking a larger one now to look at longer home treatment.

Just over half of participants were able to get into a comprehensive addiction treatment program by the end of the pilot trial. Results were reported in a letter in Thursday’s New England Journal of Medicine.

In a second letter in the journal, doctors working with the Gloucester, Massachusetts, police department report on a project to curb overdoses – the Angel Program – which offers referral and transportation to treatment programs without arrest.

Gloucester’s program averaged more than a case a day in its first year of operation. From June 2015 through last May, 376 people sought help a total of 429 times. About 37 percent of them lived in Gloucester or the surrounding county, 40 percent were from other parts of the state, 17 percent were homeless, and the rest were from other states.

Similar projects have been adopted by 153 other police departments in 28 states, researchers report.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50